Loading...

Timothy F Cloughesy

Title(s)Professor of Clinical , Neurology
SchoolMedicine
Address710 Westwood Plaza C109
Los Angeles CA 90024
Phone3108255321
vCardDownload vCard
    Other Positions
    Title(s)Professor, Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Consortium Therapeutic Studies of Primary Central Nervous System Malignancies
    NIH/NCI U01CA105695May 14, 2004 - Dec 31, 2008
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Sci Rep. 2020 Jul 17; 10(1):11922. Yao J, Hagiwara A, Raymond C, Shabani S, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 32681084.
      View in: PubMed   Mentions:    Fields:    
    2. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 Jun 12; JCO1903327. Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. PMID: 32530764.
      View in: PubMed   Mentions:    Fields:    
    3. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. Neuro Oncol. 2020 Jun 09. Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Chung C, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Rosen BR, Ellingson BM, Schmainda KM. PMID: 32516388.
      View in: PubMed   Mentions:    Fields:    
    4. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020 May 20. Reardon DA, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams JH, Li R, Taylor CT, Lassman AB. PMID: 32436060.
      View in: PubMed   Mentions:    Fields:    
    5. Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro Oncol. 2020 May 15; 22(5):694-704. Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Yakov N, Mendel I, Breitbart E, Wen PY. PMID: 31844886.
      View in: PubMed   Mentions: 2     Fields:    
    6. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, Wen PY. PMID: 31844890.
      View in: PubMed   Mentions: 3     Fields:    
    7. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery. 2020 May 04. Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 32365185.
      View in: PubMed   Mentions:    Fields:    
    8. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proc Natl Acad Sci U S A. 2020 May 19; 117(20):11085-11096. Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, Pellegrini M, Zemke NR, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. PMID: 32358191.
      View in: PubMed   Mentions:    Fields:    
    9. Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment. Neuro Oncol. 2020 Apr 24. Huang RY, Young RJ, Ellingson BM, Veeraraghavan H, Wang W, Tixier F, Um H, Nawaz R, Luks T, Kim J, Gerstner ER, Schiff D, Peters KB, Mellinghoff IK, Chang S, Cloughesy TF, Wen PY. PMID: 32328652.
      View in: PubMed   Mentions:    Fields:    
    10. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro Oncol. 2020 Apr 24. Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. PMID: 32328653.
      View in: PubMed   Mentions: 1     Fields:    
    11. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clin Cancer Res. 2020 Apr 08. Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. PMID: 32269051.
      View in: PubMed   Mentions:    Fields:    
    12. Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. J Neurooncol. 2020 May; 147(3):643-652. Cho N, Wang C, Raymond C, Kaprealian T, Ji M, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 32239430.
      View in: PubMed   Mentions:    Fields:    
    13. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa009. Ji MS, Eldred BSC, Liu R, Pianka ST, Molaie D, Kevan B, Pan S, Lai TJ, Nguyen NT, Chow FE, Yong WH, Cox CD, Reeh DN, Li T, Liau LM, Nghiemphu PL, Cloughesy TF, Li G, Lai A. PMID: 32118206.
      View in: PubMed   Mentions:
    14. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. J Neurooncol. 2020 Mar; 147(1):135-145. Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 31981013.
      View in: PubMed   Mentions:    Fields:    
    15. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020 Apr 15; 26(8):1820-1828. Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. PMID: 31937616.
      View in: PubMed   Mentions:    Fields:    
    16. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019 12 17; 21(12):1498-1508. Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN. PMID: 31276167.
      View in: PubMed   Mentions: 3     Fields:    
    17. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. PMID: 31853198.
      View in: PubMed   Mentions:
    18. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249. Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 31155679.
      View in: PubMed   Mentions:    Fields:    
    19. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY. PMID: 31215634.
      View in: PubMed   Mentions:    Fields:    
    20. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Mol Cancer Ther. 2019 09; 18(9):1565-1576. McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ. PMID: 31270152.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    21. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001. Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 31175098.
      View in: PubMed   Mentions: 1     Fields:    
    22. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 2019 08; 84(2):327-336. Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. PMID: 31154523.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    23. Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. CNS Oncol. 2019 06 01; 8(2):CNS35. Liu LY, Ji MS, Nguyen NT, Chow FE, Molaie DM, Pianka ST, Green RM, Liau LM, Ellingson BM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 31293169.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma. J Clin Endocrinol Metab. 2019 06 01; 104(6):2395-2402. Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH, Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green RM, Welsh CT, Xiong Z, Heaney AP. PMID: 30722009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 May 04. Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. PMID: 31066901.
      View in: PubMed   Mentions: 1     Fields:    
    26. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. J Neurooncol. 2019 May; 142(3):423-434. Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu PL, Yong W, Cloughesy T, Lai A. PMID: 30838489.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    27. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep. 2019 02 26; 9(1):2846. Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. PMID: 30808879.
      View in: PubMed   Mentions:    Fields:    
    28. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neurooncol. 2019 May; 142(3):587-595. Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 30806888.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    30. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. PMID: 30715997.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    31. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clin Cancer Res. 2019 03 15; 25(6):1913-1922. Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong WH, Cloughesy TF, Liau LM, Herold-Mende C, Prins RM. PMID: 30498094.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    32. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Neuro Oncol. 2018 10 09; 20(11):1525-1535. Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF. PMID: 29897562.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    33. Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Sci Rep. 2018 09 26; 8(1):14429. Smedley NF, Ellingson BM, Cloughesy TF, Hsu W. PMID: 30258190.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neurooncol Pract. 2019 Mar; 6(2):103-111. Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, Lai A. PMID: 31386050.
      View in: PubMed   Mentions:
    35. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. PMID: 29660005.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    36. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 09 03; 20(10):1383-1392. Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T. PMID: 29762717.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    37. Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography. 2018 Sep; 4(3):123-137. Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 30320212.
      View in: PubMed   Mentions: 3     Fields:    
    38. Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. Neurooncol Pract. 2019 May; 6(3):194-202. Dovek L, Nguyen NT, Ozer BH, Li N, Elashoff RM, Green RM, Liau L, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 31386024.
      View in: PubMed   Mentions:
    39. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. PMID: 29660006.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    40. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. Eur J Cancer. 2018 09; 101:95-104. Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M. PMID: 30036741.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Neuro Oncol. 2018 07 05; 20(8):1144. Lee EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY. PMID: 29955870.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043. Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 29518210.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    43. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29958537.
      View in: PubMed   Mentions: 2     Fields:    
    44. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. J Neurooncol. 2018 Sep; 139(3):651-659. Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM. PMID: 29855771.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29843811.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    46. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol. 2018 Sep; 139(2):399-409. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. PMID: 29679199.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. PMID: 29106665.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    48. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med. 2018 11; 80(5):1962-1978. Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. PMID: 29626359.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    49. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018 03 27; 20(4):457-471. Ellingson BM, Wen PY, Cloughesy TF. PMID: 29040703.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. Neuro Oncol. 2018 03 27; 20(4):557-566. Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W. PMID: 29016943.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    51. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. Mol Cancer Res. 2018 06; 16(6):947-960. Li T, Cox CD, Ozer BH, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 29545476.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    52. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget. 2018 Mar 23; 9(22):16087-16098. Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. PMID: 29662628.
      View in: PubMed   Mentions: 2     Fields:    
    53. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. PMID: 29016998.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    54. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. PMID: 29036345.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    55. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1195-1203. Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A. PMID: 29722661.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    56. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448. Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. PMID: 29266174.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    57. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. PMID: 29074604.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    58. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017 Nov; 23(11):1342-1351. Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA. PMID: 29035366.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    59. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan; 136(1):79-86. Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. PMID: 28988377.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    60. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathol. 2018 Jan; 35(1):1-9. Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, Gordon LK, Wadehra M, Yang I. PMID: 28887715.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. PMID: 28874539.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    62. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 02 15; 24(4):737-743. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. PMID: 28814435.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    63. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J Neurooncol. 2017 Sep; 134(2):357-362. Yu A, Faiq N, Green S, Lai A, Green R, Hu J, Cloughesy TF, Mellinghoff I, Nghiemphu PL. PMID: 28669012.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    64. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. PMID: 28655794.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    65. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Exp Mol Pathol. 2017 08; 103(1):87-93. Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, Lucey GM, Wei B, Mareninov S, Wang MW, Ng DW, Tashjian RS, Magaki S, Perez-Rosendahl M, Yang I, Khanlou N, Vinters HV, Liau LM, Nghiemphu PL, Lai A, Cloughesy TF, Yong WH. PMID: 28663030.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    66. Adult Glioblastoma. J Clin Oncol. 2017 Jul 20; 35(21):2402-2409. Alexander BM, Cloughesy TF. PMID: 28640706.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    67. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Mol Cell. 2017 Jul 06; 67(1):128-138.e7. Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS. PMID: 28648777.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    68. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 06 01; 19(6):796-807. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 28115578.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    69. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017 Aug; 134(1):177-188. Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. PMID: 28547590.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    70. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. PMID: 28453751.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    71. NovoTTF: where to go from here? Neuro Oncol. 2017 05 01; 19(5):605-608. Cloughesy TF, Lassman AB. PMID: 28453750.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. J Nucl Med. 2017 May; 58(5):689-696. Clark PM, Ebiana VA, Gosa L, Cloughesy TF, Nathanson DA. PMID: 28385796.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    73. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017 04; 14(2):307-320. Ellingson BM, Wen PY, Cloughesy TF. PMID: 28108885.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    74. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. 2017 03 01; 19(3):394-404. Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. PMID: 27571882.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    75. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol. 2017 04; 132(2):351-358. Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, Bergsneider M, Nghiemphu PL, Lai A, Liau LM, Cloughesy TF, Yong WH. PMID: 28161760.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    76. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. PMID: 28116649.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    77. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. J Clin Oncol. 2017 Jan 20; 35(3):343-351. Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS. PMID: 27918718.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    78. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017 Jan 20; 35(3):361-369. Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. PMID: 27893327.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    79. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. PMID: 27826680.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    80. Biomarkers in NOA-04: another piece to the puzzle. Neuro Oncol. 2016 11; 18(11):1467-1469. Lassman AB, Cloughesy TF. PMID: 27738177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    81. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14; 30(5):683-693. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS. PMID: 27746144.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    82. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3?T. NMR Biomed. 2016 11; 29(11):1563-1576. Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. PMID: 27717216.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    83. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 01; 19(1):89-98. Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. PMID: 27580889.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    84. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol. 2016 10; 18(10):1434-41. Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T. PMID: 27515827.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    85. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07; 1(10). Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 27453950.
      View in: PubMed   Mentions: 28     Fields:    
    86. Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 09 01; 34(25):3107-8. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. PMID: 27298403.
      View in: PubMed   Mentions:    Fields:    
    87. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 06 01; 8(341):341ra75. Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA. PMID: 27252174.
      View in: PubMed   Mentions: 27     Fields:    Translation:CellsCTClinical Trials
    88. Large-scale assessment of the gliomasphere model system. Neuro Oncol. 2016 10; 18(10):1367-78. Laks DR, Crisman TJ, Shih MY, Mottahedeh J, Gao F, Sperry J, Garrett MC, Yong WH, Cloughesy TF, Liau LM, Lai A, Coppola G, Kornblum HI. PMID: 27116978.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    89. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 2016 Apr 11; 29(4):563-573. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B. PMID: 27070703.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    90. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol. 2016 09; 18(9):1313-8. Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W. PMID: 27006178.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    91. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. 2016 06 01; 122(11):1718-27. Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF. PMID: 26998740.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    92. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. J Magn Reson Imaging. 2016 11; 44(5):1229-1237. Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. PMID: 26971534.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol. 2016 05; 128(1):57-66. Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. PMID: 26922345.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    94. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. PMID: 27471611.
      View in: PubMed   Mentions:
    95. Reply to T.J. Kruser et al. J Clin Oncol. 2016 Apr 10; 34(11):1282-3. Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. PMID: 26884575.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    96. Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Curr Neurol Neurosci Rep. 2016 Feb; 16(2):17. Clark PM, Mai WX, Cloughesy TF, Nathanson DA. PMID: 26759318.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    97. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol. 2016 07; 18(7):991-1001. Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. PMID: 26809751.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    98. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016 Mar 01; 34(7):731-9. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. PMID: 26786929.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    99. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7. Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. PMID: 26588662.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    100. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer. 2015 Nov 06; 14:189. Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL. PMID: 26546412.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    101. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS One. 2015; 10(10):e0141334. Yong WH, Shabihkhani M, Telesca D, Yang S, Tso JL, Menjivar JC, Wei B, Lucey GM, Mareninov S, Chen Z, Liau LM, Lai A, Nelson SF, Cloughesy TF, Tso CL. PMID: 26506620.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    102. Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. Neuroimage Clin. 2015; 9:617-24. Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM. PMID: 26740915.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    103. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. PMID: 26490307.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    104. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. PMID: 26449250.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCTClinical Trials
    105. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography. 2015 Sep; 1(1):37-43. Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 26740971.
      View in: PubMed   Mentions: 1     Fields:    
    106. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. PMID: 26250565.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    107. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 01; 22(3):508-15. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J. PMID: 26190651.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    108. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol. 2015 Sep 01; 33(25):2735-44. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. PMID: 26124478.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    109. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol. 2015 Nov; 17(11):1514-24. Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. PMID: 26113557.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    110. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol. 2015 Jun; 17(3):434-42. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. PMID: 25465392.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    111. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol. 2015 Jul 01; 33(19):2166-75. Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. PMID: 26014298.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    112. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015 Sep; 17(9):1275-83. Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. PMID: 26019185.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    113. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. PMID: 25934816.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    114. Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncol Rep. 2015 Jun; 33(6):2883-8. Hathout L, Ellingson BM, Cloughesy TF, Pope WB. PMID: 25962999.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    115. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 2015 Dec; 17(12):1589-98. Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL. PMID: 25910840.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    116. Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clin Cancer Res. 2015 Oct 01; 21(19):4373-83. Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. PMID: 25901082.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    117. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2015 May; 122(3):497-505. Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM. PMID: 25773062.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    118. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014 Dec; 11(4):255-63. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. PMID: 25610711.
      View in: PubMed   Mentions:
    119. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS One. 2014; 9(10):e99057. Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, Lai A, Cloughesy T, McKhann GM, Bruce JN, Rostomily RC, Canoll P, Swanson KR. PMID: 25350742.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    120. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. PMID: 25313237.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    121. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii2-11. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. PMID: 25313235.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    122. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res. 2014 Nov 15; 20(22):5808-22. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A. PMID: 25224277.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    123. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. PMID: 25165194.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    124. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6. Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. PMID: 24997140.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    125. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 05 22; 370(21):2049. Chinot OL, Wick W, Cloughesy T. PMID: 24860870.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    126. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014 Jul 01; 20(13):3550-9. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. PMID: 24687922.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    127. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Jun; 16(6):815-22. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. PMID: 24627236.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    128. ¹8F-FLT ???and ¹8F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014 Jun; 41(6):1199-209. Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. PMID: 24604590.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    129. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):709-22. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. PMID: 24552318.
      View in: PubMed   Mentions: 589     Fields:    Translation:HumansCTClinical Trials
    130. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 2014 May; 12(5):694-702. Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, Lasky JL. PMID: 24505127.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    131. C-terminally truncated form of aB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. J Neurooncol. 2014 Mar; 117(1):53-65. Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB. PMID: 24473683.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    132. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. PMID: 24470557.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    133. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014 Mar; 47(4-5):258-66. Shabihkhani M, Lucey GM, Wei B, Mareninov S, Lou JJ, Vinters HV, Singer EJ, Cloughesy TF, Yong WH. PMID: 24424103.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    134. Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. J Neurooncol. 2014 Feb; 116(3):601-8. Zaw TM, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Ellingson BM. PMID: 24395348.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. J Neurooncol. 2014 Jan; 116(2):373-9. Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM. PMID: 24234804.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    136. Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. J Neurooncol. 2014 Feb; 116(3):551-8. Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 24318915.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    137. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 03; 343(6166):72-6. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS. PMID: 24310612.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansAnimalsCells
    138. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 2014 Mar; 16(3):414-20. Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 24305712.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    139. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014 Apr; 16(4):603-9. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. PMID: 24305722.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    140. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. PMID: 24305708.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    141. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014 Apr; 271(1):200-10. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. PMID: 24475840.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    142. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 2013; 8(11):e80397. Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. PMID: 24260384.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    143. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15; 19(20):5722-32. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. PMID: 24030701.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    144. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014; 9:1-25. Cloughesy TF, Cavenee WK, Mischel PS. PMID: 23937436.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansAnimals
    145. Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. J Neurooncol. 2013 Jul; 113(3):365-73. Mareninov S, De Jesus J, Sanchez DE, Kay AB, Wilson RW, Babic I, Chen W, Telesca D, Lou JJ, Mirsadraei L, Gardner TP, Khanlou N, Vinters HV, Shafa BB, Lai A, Liau LM, Mischel PS, Cloughesy TF, Yong WH. PMID: 23640138.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    146. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013 May; 13(5):347. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF. PMID: 23529375.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    147. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle. 2013 May 15; 12(10):1473-4. Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. PMID: 23624839.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    148. De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. PMID: 23533263.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    149. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013 Sep; 23(5):565-73. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, Martinez-Lage M, Robinson AE, Yong WH, Cloughesy T, Lai A, Phillips HS, Marshall R, Mueller S, Haas-Kogan DA, Molinaro AM, Perry A. PMID: 23438035.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    150. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. PMID: 23565532.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    151. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013 May; 15(5):626-34. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, Chowdhury R, Phillips HS, Nghiemphu PL, Behbahanian Y, Ellingson BM. PMID: 23444259.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    152. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):609-15. Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. PMID: 23462418.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    153. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res. 2013 May 15; 73(10):2976-86. Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. PMID: 23400596.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    154. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb; 36(2):152-7. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. PMID: 23377664.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    155. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. J Neurooncol. 2013 Apr; 112(2):257-66. Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM. PMID: 23344788.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    156. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. PMID: 23345034.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    157. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS One. 2013; 8(1):e51951. Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. PMID: 23372647.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    158. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013 Mar; 15(3):370-81. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. PMID: 23328811.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    159. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro Oncol. 2013 Mar; 15(3):382-90. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. PMID: 23275575.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    160. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013 Jan; 15(1):4-27. Weller M, Cloughesy T, Perry JR, Wick W. PMID: 23136223.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    161. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013 Jan; 15(1):57-68. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A. PMID: 23115158.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    162. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. PMID: 23099651.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    163. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clin. 2013 Apr; 8(2):201-17. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PMID: 27157948.
      View in: PubMed   Mentions: 1     Fields:    
    164. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012 Dec; 14(12):1465-72. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. PMID: 23090985.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    165. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 03; 104(19):1458-69. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. PMID: 22945948.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    166. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012 Nov; 110(2):245-50. Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. PMID: 22918789.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    167. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. PMID: 22923449.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    168. Glioblastoma therapy in the elderly: one age does not fit all. Lancet Oncol. 2012 Sep; 13(9):857-8. Nghiemphu PL, Cloughesy T. PMID: 22877850.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    169. Bevacizumab as first-line therapy for glioblastoma. Future Oncol. 2012 Aug; 8(8):929-38. Piccioni D, Lai A, Nghiemphu P, Cloughesy T. PMID: 22894667.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    170. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012 Aug; 14(8):1079-89. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. PMID: 22711609.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    171. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. J Neuroimaging. 2014 Jan-Feb; 24(1):23-30. White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, Nghiemphu PL, Wang JJ, Cloughesy TF, Ellingson BM. PMID: 22672084.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    172. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. PMID: 22661585.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    173. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. PMID: 22649140.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    174. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. PMID: 22554547.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    175. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. PMID: 22588883.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCells
    176. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. PMID: 22426926.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    177. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. PMID: 22392572.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    178. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med. 2012 Mar; 53(3):393-8. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. PMID: 22323780.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    179. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging. 2012 Jun; 35(6):1472-7. Ellingson BM, Zaw T, Cloughesy TF, Naeini KM, Lalezari S, Mong S, Lai A, Nghiemphu PL, Pope WB. PMID: 22281731.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    180. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012 Mar; 14(3):333-43. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. PMID: 22270220.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    181. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012 Jan; 53(1):29-36. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. PMID: 22159180.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    182. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. Semin Oncol. 2011 Dec; 38 Suppl 4:S11-20. Cloughesy T. PMID: 22078643.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    183. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 01; 29(34):4482-90. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. PMID: 22025148.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansCells
    184. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012 Mar; 107(1):197-205. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. PMID: 22015945.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    185. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res. 2011 Dec; 9(12):1668-85. Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, Cloughesy TF, Kornblum HI, Nelson SF, Liau LM, Tso CL. PMID: 22013079.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    186. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. PMID: 21984222.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    187. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012 Jan 16; 59(2):908-16. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A. PMID: 22001163.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    188. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. PMID: 22059152.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    189. Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov; 1(6):524-38. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. PMID: 22145100.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCells
    190. Discriminant analysis of ¹8F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011 Oct 15; 17(20):6553-62. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. PMID: 21868765.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    191. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Oct; 13(10):1151-61. Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. PMID: 21856685.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    192. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. PMID: 21813511.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    193. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. PMID: 21768451.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    194. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. PMID: 21739168.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    195. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012 Jan; 106(1):111-9. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. PMID: 21706273.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    196. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2012 Jan; 67(1):237-45. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. PMID: 21702063.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    197. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. PMID: 21636710.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    198. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. PMID: 21632852.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    199. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. PMID: 21606416.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    200. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. PMID: 21558074.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    201. High order diffusion tensor imaging in human glioblastoma. Acad Radiol. 2011 Aug; 18(8):947-54. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. PMID: 21536466.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    202. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2011 Oct; 105(1):91-101. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. PMID: 21442275.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    203. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Apr; 13(4):401-9. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. PMID: 21324937.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    204. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. PMID: 21310734.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    205. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. PMID: 21297127.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    206. Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment. J Clin Pathol. 2011 Jul; 64(7):634-6. Kay AB, Estrada DK, Mareninov S, Silver SS, Magyar CE, Dry SM, Cloughesy TF, Yong WH. PMID: 21217091.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    207. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res. 2011 Jan 01; 17(1):6-11. Cloughesy TF, Mischel PS. PMID: 21208902.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    208. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. PMID: 21147867.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    209. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011 Jan 10; 29(2):142-8. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. PMID: 21135282.
      View in: PubMed   Mentions: 177     Fields:    Translation:HumansCTClinical Trials
    210. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. PMID: 21084434.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    211. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1422-7. Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF. PMID: 20934264.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    212. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer. 2010 Oct; 55(4):644-51. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. PMID: 20589659.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    213. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J Neurooncol. 2011 May; 102(3):477-84. Solis OE, Mehta RI, Lai A, Mehta RI, Farchoukh LO, Green RM, Cheng JC, Natarajan S, Vinters HV, Cloughesy T, Yong WH. PMID: 20872044.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    214. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010 Oct; 51(10):1532-8. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. PMID: 20847166.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    215. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010 Oct; 12(10):1061-70. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. PMID: 20615922.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    216. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med. 2010; 3:79-85. Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. PMID: 23226044.
      View in: PubMed   Mentions:
    217. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010 Aug; 12(8):882-9. Akhavan D, Cloughesy TF, Mischel PS. PMID: 20472883.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    218. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010 May; 51(5):720-7. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. PMID: 20395318.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    219. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. PMID: 20231676.
      View in: PubMed   Mentions: 970     Fields:    Translation:Humans
    220. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Front Neurosci. 2009; 3:57. Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. PMID: 20582289.
      View in: PubMed   Mentions:
    221. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 20009104.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    222. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. PMID: 20150372.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    223. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. PMID: 20150371.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    224. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. PMID: 19293394.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    225. Genomic landscape of meningiomas. Brain Pathol. 2010 Jul; 20(4):751-62. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. PMID: 20015288.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    226. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. PMID: 19720927.
      View in: PubMed   Mentions: 822     Fields:    Translation:HumansCTClinical Trials
    227. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. PMID: 19690143.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    228. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol. 2010 Feb; 96(3):359-67. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. PMID: 19655089.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    229. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes Dev. 2009 Aug 01; 23(15):1699-704. Iwanami A, Cloughesy TF, Mischel PS. PMID: 19651981.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    230. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. PMID: 19625624.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansAnimalsCells
    231. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul; 252(1):182-9. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. PMID: 19561256.
      View in: PubMed   Mentions: 143     Fields:    Translation:Humans
    232. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics. 2009 Jul; 6(3):500-12. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. PMID: 19560740.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    233. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. PMID: 19562255.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    234. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol. 2009 Aug; 94(1):1-19. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. PMID: 19468690.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    235. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009 Apr; 27(4):980-7. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. PMID: 19353526.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansAnimalsCells
    236. A tool for improving the longitudinal imaging characterization for neuro-oncology cases. AMIA Annu Symp Proc. 2008 Nov 06; 712-6. Taira RK, Taira R, Bui A, Bui AA, Hsu W, Bashyam V, Dube S, Watt E, Andrada L, El-Saden S, Cloughesy T, Kangarloo H. PMID: 18999139.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    237. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. PMID: 18981465.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansCTClinical Trials
    238. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008 Oct 21; 1:52. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. PMID: 18940004.
      View in: PubMed   Mentions: 86     Fields:    
    239. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan; 91(2):183-9. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. PMID: 18850068.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    240. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008 Oct; 249(1):268-77. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. PMID: 18796682.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    241. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro Oncol. 2009 Feb; 11(1):22-32. Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A. PMID: 18812520.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    242. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan; 91(2):175-82. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. PMID: 18797818.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    243. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. PMID: 18559968.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    244. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009 Aug; 71(2):242-8. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. PMID: 18511228.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    245. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008 Jun; 10(3):355-60. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. PMID: 18436627.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    246. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008 Jul; 88(3):339-47. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. PMID: 18389177.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    247. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1372-80. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. PMID: 18355978.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    248. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD. PMID: 18356283.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    249. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22; 5(1):e8. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. PMID: 18215105.
      View in: PubMed   Mentions: 239     Fields:    Translation:HumansCellsCTClinical Trials
    250. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15; 14(2):488-93. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel PS. PMID: 18223223.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    251. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008 Jan; 86(1):48-60. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, Kornblum HI. PMID: 17722061.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    252. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD. PMID: 18094423.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    253. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. PMID: 18056194.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    254. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20; 25(30):4714-21. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. PMID: 17947718.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    255. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007 Oct; 48(10):1651-61. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. PMID: 17873130.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    256. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May; 61(6):1059-67. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. PMID: 17694310.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    257. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007 May 01; 13(9):2592-8. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. PMID: 17473188.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    258. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007 Jul; 34(7):1003-11. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. PMID: 17295039.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    259. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):378-81. Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 17255257.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    260. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. PMID: 17031561.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    261. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006 Sep; 4(9):607-19. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. PMID: 16966431.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCells
    262. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. PMID: 16914578.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCTClinical Trials
    263. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. PMID: 16912159.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    264. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 01; 24(22):3651-6. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. PMID: 16877733.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    265. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun; 47(6):904-11. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. PMID: 16741298.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    266. Using molecular information to guide brain tumor therapy. Nat Clin Pract Neurol. 2006 May; 2(5):232-3. Mischel PS, Cloughesy T. PMID: 16932555.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    267. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. PMID: 16533878.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    268. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006 Jan 01; 66(1):159-67. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. PMID: 16397228.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    269. Content based image retrieval for MR image studies of brain tumors. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:3337-40. Dube S, El-Saden S, Cloughesy TF, Sinha U. PMID: 17946561.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    270. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. PMID: 16282176.
      View in: PubMed   Mentions: 501     Fields:    Translation:HumansCells
    271. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005 Nov-Dec; 26(10):2466-74. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. PMID: 16286386.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    272. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56. Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. PMID: 16170172.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    273. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD. PMID: 16012795.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    274. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 01; 11(15):5515-25. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. PMID: 16061868.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansCellsCTClinical Trials
    275. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun; 46(6):945-52. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. PMID: 15937304.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    276. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res Mol Brain Res. 2005 May 20; 136(1-2):99-103. Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. PMID: 15893592.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    277. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 2005 Jul 22; 280(29):26953-64. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. PMID: 15908427.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    278. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004 Dec; 3(12):1243-9. Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. PMID: 15611621.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    279. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. PMID: 15514370.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    280. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. PMID: 15292713.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    281. Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 2004 Nov; 20(4):260-72. Graham CA, Cloughesy TF. PMID: 15612602.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    282. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004 Oct; 5(10):782-92. Mischel PS, Cloughesy TF, Nelson SF. PMID: 15378038.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimals
    283. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004 Sep 15; 64(18):6503-10. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. PMID: 15374961.
      View in: PubMed   Mentions: 254     Fields:    Translation:Humans
    284. Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol. 2004 Mar-Apr; 67(1-2):245-53. Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J. PMID: 15072475.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    285. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 2004 Feb 12; 23(6):1283-90. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. PMID: 14961077.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    286. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol. 2004 Feb; 66(3):365-75. Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. PMID: 15015670.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    287. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. PMID: 14769140.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    288. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 2004 Jan; 84(1):8-20. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. PMID: 14631378.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    289. Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF. PMID: 14635616.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    290. Oncodiagnosis panel: 2002. Metastatic NSCLC. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF. PMID: 14628846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    291. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003 Jul 31; 22(31):4918-23. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. PMID: 12894235.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    292. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M. PMID: 12805331.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    293. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003 Jun 01; 63(11):2742-6. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. PMID: 12782577.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCells
    294. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003 May 01; 97(9 Suppl):2381-6. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. PMID: 12712460.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    295. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2003 May-Jun; 2(3):242-7. Mischel PS, Nelson SF, Cloughesy TF. PMID: 12878856.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    296. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003 Apr 17; 22(15):2361-73. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. PMID: 12700671.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    297. Targeted molecular therapy of GBM. Brain Pathol. 2003 Jan; 13(1):52-61. Mischel PS, Cloughesy TF. PMID: 12580545.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    298. Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging. Magn Reson Med. 2002 Sep; 48(3):411-8. Alger JR, Frew AJ, Cloughesy TF, Del Vecchio W, Villablanca JP, Curran JG. PMID: 12210904.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    299. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002 Sep; 8(9):2894-901. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. PMID: 12231534.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    300. Predicting major depression in brain tumor patients. Psychooncology. 2002 May-Jun; 11(3):230-8. Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. PMID: 12112483.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    301. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002 Apr; 25(2):204-8. Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. PMID: 11943904.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    302. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14. Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. PMID: 11916502.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    Timothy's Networks
    Concepts (683)
    Derived automatically from this person's publications.
    _
    Co-Authors (94)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _